Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Imugene Limited
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04432207CT.gov A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Imu-201 (Pd1-Vaxx) (this asset) | Imugene Limited | P1 | CC · 43 |
| Carboplatin | Guangdong Association of Clinical Trials | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Guangdong Association of Clinical Trials | P3 | BB |
| Cyclophosphamide | Anusha Kalbasi | P2 | BB |
| Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Nivolumab | Emory University | P3 | BB |
| Gefitinib | Fujian Cancer Hospital | P3 | BB |
| Etoposide | Guangdong Association of Clinical Trials | P3 | BB |
| Vinorelbine Ditartrate | AIO-Studien-gGmbH | P3 | BB |
+42 more in the Lung Adenocarcinoma cohort
Other indications for Imu-201 (Pd1-Vaxx)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P1 | CC · 43 |
| Lung Large Cell Carcinoma | — | P1 | CC · 43 |
| Colorectal Cancer | — | P2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Imu-201 (Pd1-Vaxx) in Lung Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/imu-201-pd1-vaxx-lung-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →